$FTLF

FitLife Brands Announces First Quarter Earnings Call

OMAHA, NE, May 05, 2025 ( GLOBE NEWSWIRE ) -- FitLife Brands, Inc. ( "FitLife," or the "Company" ) ( Nasdaq: FTLF ) , a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the first quarter of ...

Original reporting
GlobeNewswire · FitLife Brands, Inc.
Published May 5, 2025, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 5, 2025, 7:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FitLife Brands Announces First Quarter Earnings Call — source image
Decision brief

The 30-second read

$FTLFBullishMed
01

Why it matters

The upcoming earnings report is highly anticipated; positive results could reinforce growth trends, while negative results may cause volatility.

02

Market read

The earnings call is relevant for traders and investors focusing on health and wellness sectors, with potential short-term trading opportunities.

03

What to watch

Market-wide volatility or macroeconomic factors could overshadow company-specific news, limiting impact.

Timing: Immediate, as the earnings call is scheduled soon.

Background

FitLife Brands is a provider of nutritional supplements and wellness products, with recent growth driven by product innovation.

Company-level read

Ticker impact

$FTLFBullishHigh confidence
Context

The news pertains directly to FitLife Brands, Inc., providing financial performance updates that can influence its stock price.

Expected impact

Moderate upward movement expected within the next 1-2 trading sessions.

Evidence & confidence

Earnings reports often lead to increased trading activity and potential price adjustments. The bullish sentiment score (0.377) supports a positive outlook, especially if earnings meet or exceed expectations.

Market effects

Potential positive impact on the nutritional supplements and wellness sector due to increased investor interest.

Limited regional impact; primarily affects the company's primary trading region.

Minimal; the news is company-specific with limited global market influence.

Counterpoint

Disappointing earnings or guidance could lead to a short-term decline, offsetting initial positive reactions.

Key entities

  • FitLife Brands, Inc.

    A provider of nutritional supplements and wellness products.

Related articles

$FTLFMed

FitLife Brands (FTLF) Q2 2026 Earnings Call Transcript

FitLife Brands (FTLF) reported Q2 2026 earnings. Legacy FitLife's gross margin rose to 41.7%, but contribution fell 25.9% to $4.2M. Irwin's revenue hit $14.1M, with Amazon sales growing. The company is improving supply chain, product development, and marketing. SG&A costs dropped 3.8% sequentially. The term loan balance is $36.1M, with $8.6M of debt paid since the Irwin acquisition.

$FTLFMed

FitLife Brands Q2 Earnings Call Highlights

FitLife Brands (NASDAQ:FTLF) reported Q2 call highlights. Irwin direct Amazon sales rose from about $500k monthly in Dec 2025 to about $1m in June 2026, with July comparable to June. Legacy revenue fell 23% YoY to $12.4m; gross margin 41.7%. FitLife is extending Irwin shelf life and launching new products. It paid about $1.5m term-loan, cutting term-loan to $36.1m.

$FTLFMed

FITLIFE BRANDS, INC. (FTLF): Results of Operations and Financial Condition

FITLIFE BRANDS, INC. (FTLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FitLife Brands Announces Second Quarter 2026 Results OMAHA, NE – August 13, 2026 – FitLife Brands, Inc. (“ FitLife ” or the “ Company ”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.